What Is Similar to Quaalude? Modern Drugs and Their Dangers

Several modern drug classes produce effects that overlap substantially with those of methaqualone, the sedative-hypnotic sold under the brand name Quaalude from the 1960s through the early 1980s. Benzodiazepines, Z-drugs, GHB, carisoprodol, and a growing roster of designer sedatives all target the brain’s inhibitory signaling system in ways that create similar sedation, euphoria, muscle relaxation, and disinhibition. None are pharmacological clones of methaqualone, though, and each carries a distinct risk profile that anyone curious about this topic should understand.

How Quaaludes Worked in the Brain

Methaqualone belongs to a chemical family called quinazolinones. It produces its sedative and euphoric effects by amplifying the activity of GABA-A receptors, the brain’s main “slow down” switches. What made methaqualone pharmacologically unusual is that it did not bind to the same spots on those receptors that benzodiazepines or barbiturates use. Instead, it latched onto a transmembrane interface between receptor subunits, a site that overlaps with the binding pocket used by the general anesthetics propofol and etomidate.¹ This distinct binding site helps explain why Quaaludes felt different from a Valium or a barbiturate even though all three drug classes ultimately boosted GABA signaling.²

Methaqualone also showed a surprisingly varied repertoire across different GABA-A receptor subtypes. At some subtypes it boosted receptor activity, at others it dampened it, and at certain combinations it acted as a “superagonist” that could drive the receptor harder than GABA itself.² That complex pharmacology likely contributed to the drug’s particular blend of relaxation, euphoria, and loss of inhibition that made it one of the most widely misused prescription drugs of the 1970s.³

Benzodiazepines Are the Closest Mainstream Successor

When methaqualone was pulled from the U.S. market in the mid-1980s, benzodiazepines had already largely replaced it in medical practice. Drugs like diazepam (Valium), alprazolam (Xanax), and clonazepam (Klonopin) target GABA-A receptors at a different binding site than methaqualone, the so-called benzodiazepine site, but the downstream effect is similar: sedation, muscle relaxation, reduced anxiety, and at higher doses, euphoria. The subjective experience of a high-dose benzodiazepine is probably the closest thing most people today will encounter to a Quaalude, though users who experienced both drugs in the 1970s and 1980s generally describe Quaaludes as producing a warmer, more distinctly euphoric feeling.

Benzodiazepines come with their own serious dangers. One of the most clinically significant is anterograde amnesia, the inability to form new memories while under the drug’s influence.⁴ This blackout effect means you can engage in complex behaviors, conversations, and even driving while retaining no memory of any of it. Methaqualone produced similar amnesia and disinhibition at recreational doses. Both drug classes also carry meaningful dependence risk. Benzodiazepine withdrawal can produce seizures, hallucinations, and delirium that closely mirror severe alcohol withdrawal, which is itself treated with benzodiazepines because the two substances share enough pharmacology that one can substitute for the other during detox.⁵

Z-Drugs and the Sleep Aid Connection

Zolpidem (Ambien), zopiclone, and zaleplon are collectively called Z-drugs. They are not chemically related to benzodiazepines, but they act on the same GABA-A receptor binding site and produce pharmacologically similar effects: sedation, hypnosis, and at higher-than-prescribed doses, a disinhibited, dreamy state that some users compare to the Quaalude experience.⁶ Z-drugs were originally marketed as safer alternatives to benzodiazepines for insomnia, with supposedly lower abuse potential. That turned out to be overly optimistic. Recreational misuse of zolpidem in particular is well documented, and dependence develops along similar timelines as with benzodiazepines.

The danger specific to Z-drugs is their tendency to produce complex sleep behaviors: sleepwalking, sleep-eating, and even sleep-driving, sometimes with complete amnesia for the episode. The FDA eventually added its strongest boxed warning to all three Z-drugs for this reason. In the context of “what’s like a Quaalude,” Z-drugs land in a strange middle ground: they are less overtly euphoric for most people, but the dissociated, disinhibited state they produce shares significant overlap with the Quaalude experience, particularly the memory-erasing aspect.

GHB and the Club Drug Overlap

Gamma-hydroxybutyrate, or GHB, is a naturally occurring brain chemical that also exists as a potent recreational depressant. Its effects at low doses include euphoria, sociability, and loss of inhibition. At moderate doses, it produces deep sedation and muscle relaxation. At high doses, it can cause unconsciousness, respiratory depression, and death.⁷ The margin between a recreational dose and a dangerous one is alarmingly thin. Blood levels that produce euphoria and disinhibition can be as little as one-fifth of the concentration that produces fatal cardiorespiratory collapse.⁷

GHB’s mechanism is not identical to methaqualone’s. It acts primarily through its own specific receptor as well as GABA-B receptors, rather than the GABA-A receptors that methaqualone, benzodiazepines, and barbiturates target. But the felt experience at low-to-moderate doses, particularly the warm euphoria combined with physical relaxation and lowered inhibitions, is the closest subjective parallel to a Quaalude that many recreational drug users report. GHB also shares methaqualone’s notorious reputation for being used to incapacitate people, earning it the grim “date-rape drug” label.

Carisoprodol (Soma)

Carisoprodol, sold as Soma, is a prescription muscle relaxant that occupies an odd niche in this landscape. It is prescribed for short-term relief of musculoskeletal pain, but its sedative effects have made it a target for recreational misuse. Carisoprodol’s primary metabolite is meprobamate, an older sedative-hypnotic from the same era as methaqualone, and meprobamate acts directly on GABA-A receptors. Research has shown that carisoprodol itself, not just its metabolite, can modulate GABA-A receptor function in ways similar to other central nervous system depressants.⁸

People who misuse Soma at high doses describe a heavy, dreamy sedation with euphoria and muscle relaxation, a profile that echoes the Quaalude experience. The impairment it produces, particularly in driving, is consistent with other central nervous system depressants and closely resembles alcohol intoxication.⁹ Because carisoprodol is still legally prescribed and widely available, it represents one of the more accessible drugs that produces Quaalude-like effects, and it is increasingly recognized as having real addiction potential.

Designer Methaqualone Analogs

For people specifically seeking the methaqualone experience, an underground market in designer analogs has emerged over the past decade. Chemists modify the quinazolinone backbone of methaqualone just enough to skirt drug scheduling laws, producing compounds with names like SL-164, methylmethaqualone, etaqualone, and a growing list of others. These analogs are sold through online research chemical vendors, often with minimal information about their potency or safety.

This is where the danger escalates sharply. Newly developed methaqualone analogs are available online and represent a serious, underrecognized threat because of their high potency and very low effective doses.¹⁰ A person accustomed to dosing methaqualone at hundreds of milligrams could easily overdose on an analog active at a fraction of that amount. To make matters worse, standard toxicology screens in emergency departments do not detect these compounds. In one documented intoxication case involving the analog SL-164, identification required specialized mass spectrometry equipment and a time-consuming investigative procedure before clinicians even knew what the patient had taken.¹¹

Original methaqualone also persists in the illicit market in parts of the world, particularly southern Africa, where it is known as Mandrax. There, tablets are typically crushed and mixed with cannabis before being smoked, a route of administration that delivers a rapid, intense high.¹² The continued underground demand for methaqualone, whether as Mandrax in South Africa or designer analogs sold online elsewhere, underscores that a market for this specific drug experience has never fully disappeared.

Designer Benzodiazepines

Running parallel to designer methaqualone analogs is a larger and more established market in designer benzodiazepines. These are structurally modified versions of prescription benzodiazepines, engineered to evade scheduling. Compounds like clonazolam, flualprazolam, and bromazolam have gained significant traction in underground markets. The effects recreational users describe include heavy sedation, euphoria, amnesia, and rapid development of tolerance.¹³

Some of these designer benzodiazepines are extraordinarily potent. Clonazolam, for instance, is reported to be more than twice as potent as alprazolam, meaning a dose measured in fractions of a milligram can produce complete sedation and blackout.¹³ The practical consequence is that tiny dosing errors become life-threatening. And like methaqualone analogs, designer benzodiazepines often go undetected on standard hospital drug screens, leaving emergency physicians to treat overdoses without knowing what substance they are dealing with.

Chloral Hydrate and Other Legacy Sedatives

Before methaqualone, before benzodiazepines, there were older sedative-hypnotics like chloral hydrate, the original “Mickey Finn” of crime fiction. Chloral hydrate is still technically available in some countries and occasionally surfaces in forensic cases. It produces sedation through mechanisms partly involving GABA-A receptors, and at high doses creates a heavy, intoxicated state with features similar to methaqualone or barbiturate overdose.

Chloral hydrate is worth mentioning here because it illustrates a recurring pattern in sedative pharmacology. It was marketed as safer than its predecessors, then turned out to carry serious risks including fatal overdose, cardiac rhythm disturbances, and dependence.¹⁴ Lethal doses can be as low as five grams, and fatalities have been documented in people with concurrent alcohol dependence, a common comorbidity among heavy sedative users.¹⁵ The same trajectory played out with methaqualone itself: initially promoted as a safe, nonaddicting alternative to barbiturates, it proved to cause both physical and psychological dependence within years of widespread use.³ By the time reviews were comparing methaqualone to barbiturates, the conclusion was blunt: it offered no meaningful advantage.¹⁶

Why Mixing Any of These Drugs Is Especially Dangerous

One of the most critical things to understand about all Quaalude-like substances is that their dangers multiply when combined. Because benzodiazepines, Z-drugs, GHB, barbiturates, alcohol, and opioids all depress the central nervous system through overlapping pathways, combining even two of them can produce respiratory failure out of proportion to what either drug would cause alone. Coadministration of opioids with benzodiazepines or alcohol produces a defined increase in rates of overdose and death.¹⁷

This synergistic lethality is not some theoretical concern. It is the leading mechanism in sedative overdose deaths. A person who tolerates a certain dose of a benzodiazepine on its own may stop breathing after adding two drinks or a single opioid pill. The same was true of methaqualone in its era: most Quaalude fatalities involved combinations with alcohol or other depressants. The pharmacology has not changed, and if anything the modern landscape is more treacherous because the number of available depressant substances has expanded while their potency has increased.

The Shared Binding Site That Connects Quaaludes to Anesthetics

A detail that is pharmacologically interesting and practically relevant: methaqualone binds to the same transmembrane site on GABA-A receptors that the intravenous general anesthetics propofol and etomidate use.¹ Propofol and etomidate are the drugs anesthesiologists inject to put you under before surgery, and GABA-A receptors are a major target for their hypnotic effects.¹⁸ This overlap explains why high-dose methaqualone could induce a state approaching general anesthesia. It also helps explain why propofol has itself become a drug of abuse among a small population, predominantly healthcare workers with access to it. The euphoria-to-unconsciousness trajectory is similar, and the respiratory depression that makes propofol dangerous outside a monitored operating room is mechanistically related to why Quaalude overdoses killed people.

Etomidate and propofol are not street drugs in any conventional sense, but the shared pharmacological target highlights something important about what “similar to Quaalude” really means at the molecular level. The GABA-A receptor is the common thread running through nearly every drug on this list, from barbiturates through benzodiazepines, Z-drugs, carisoprodol, chloral hydrate, designer analogs, and general anesthetics.¹⁹ The binding sites differ, the potencies differ, and the subjective experiences are not identical, but the underlying pharmacological family tree is one big interconnected system. Anything that pushes GABA-A activity hard enough will produce sedation, amnesia, disinhibition, and, past a certain point, respiratory arrest.

A Different Approach Altogether

The newest class of prescription sleep drugs steps away from GABA-A pharmacology entirely. Dual orexin receptor antagonists, or DORAs, work by blocking the brain’s wakefulness-promoting orexin system rather than amplifying inhibitory signaling. Drugs like suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq) promote sleep by turning down the “stay awake” signal instead of forcing the “go to sleep” signal louder. Daridorexant, the most recently approved, has shown sustained efficacy over twelve months with improvements in both nighttime sleep and daytime functioning.²⁰

DORAs are relevant to this topic because they represent a conscious effort to break the cycle that has played out since chloral hydrate: a new sedative is introduced as safer than the last one, gains popularity, and then turns out to carry many of the same dependence and abuse risks. Because DORAs do not directly juice the GABA system, they produce a qualitatively different kind of sedation that lacks the euphoric punch of benzodiazepines, Z-drugs, or methaqualone. For someone seeking effective insomnia treatment without the recreational high, that is a feature. For someone seeking a Quaalude substitute, DORAs would be deeply disappointing, which is exactly why they represent progress from a public health standpoint. The pattern in sedative pharmacology has always been that drugs people enjoy taking recreationally are the ones that destroy lives at scale. Designing drugs that work for insomnia without producing euphoria is the clearest way to break that cycle, even if it means the drugs will never have the cultural cachet that Quaaludes once did.